Concept
Treatment Results
10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE / 10. Welireg Plus Lenvima for Advanced Kidney Cancer
"Approved: Sept. 24 | Read more\n\nFor clear cell kidney cancer that has grown after immunotherapy, Welireg (belzutifan) plus Lenvima (lenvatinib) delayed progression longer than Cabometyx (cabozantinib): a median of 14.6 vs 10.6 months. The difference in overall survival was not statistically significant."
Related Ideas
- September Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Kidney MonitoringFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Treatment Combination10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
- Treatment Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
- Treatment Findings10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Etcamah Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 1. Etcamah for ESR1-Mutated Breast Cancer
- Approval Withdrawal10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · One Approval That Was Taken Away
- Approval Withdrawal10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways